Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 157201, 9 pages
http://dx.doi.org/10.1155/2015/157201
Review Article

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

1Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing 100191, China
2Department of Preventive Medicine, College of Medicine, Shihezi University, Shihezi 832002, China
3Department of Physiology, Capital Medical University, Beijing 100069, China
4Department of Statistics, Graduate School of Arts and Sciences, Columbia University, New York, NY 10027, USA
5Department of Orthopedics, Tianjin Fifth Central Hospital, Tianjin 300450, China
6Shantou-Oxford Clinical Research Unit, Shantou University Medical College, Shantou 515041, China
7Department of Endocrinology and Metabolism, People’s Hospital, Peking University, Beijing 100044, China

Received 18 September 2014; Revised 12 December 2014; Accepted 22 December 2014

Academic Editor: Mitsuhiko Noda

Copyright © 2015 Feng Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [42 citations]

The following is the list of published articles that have cited the current article.

  • T. Karagiannis, A. Liakos, E. Bekiari, E. Athanasiadou, P. Paschos, D. Vasilakou, M. Mainou, M. Rika, P. Boura, D. R. Matthews, and A. Tsapas, “Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials,” Diabetes, Obesity and Metabolism, 2015. View at Publisher · View at Google Scholar
  • Lalita Prasad-Reddy, and Diana Isaacs, “A clinical review of GLP-1 receptor agonists: Efficacy and safety in diabetes and beyond,” Drugs in Context, vol. 4, 2015. View at Publisher · View at Google Scholar
  • Anthony H Barnett, “NICE draft type 2 diabetes guidelines: a cause for concern,” The Lancet Diabetes & Endocrinology, 2015. View at Publisher · View at Google Scholar
  • Akram Ahangarpour, Golshan Afshari, Seyyed Ali Mard, Ali Khodadadi, and Mahmoud Hashemitabar, “Alteration Effect of Exendin-4 on Oxidative Stress and Metabolic Disorders Induced by Bisphenol A in Adult Male Mice,” Jentashapir Journal of Health Research, vol. Inpress, no. Inpress, 2016. View at Publisher · View at Google Scholar
  • Eun Ju Lee, and Tae Nyun Kim, “Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update,” The Korean Journal of Obesity, vol. 25, no. 3, pp. 121–128, 2016. View at Publisher · View at Google Scholar
  • Howard S. Weintraub, James A. Underberg, Eugenia Gianos, Matthew H. Vorsanger, Pritha Subramanyam, Steven H. Lamm, Ira J. Goldberg, and Arthur Z. Schwartzbard, “Cardiovascular Effects of the New Weight Loss Agents,” Journal of the American College of Cardiology, vol. 68, no. 8, pp. 849–859, 2016. View at Publisher · View at Google Scholar
  • Jia Liu, Yanjin Hu, Heng Zhang, Yuan Xu, and Guang Wang, “Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes,” Journal of Diabetes and its Complications, 2016. View at Publisher · View at Google Scholar
  • Elaine Patterson, Paul M. Ryan, John F. Cryan, Timothy G. Dinan, R. Paul Ross, Gerald F. Fitzgerald, and Catherine Stanton, “Gut microbiota, obesity and diabetes,” Postgraduate Medical Journal, vol. 92, no. 1087, pp. 286–300, 2016. View at Publisher · View at Google Scholar
  • Rosaria Vincenza Giglio, Angelo Maria Patti, Dragana Nikolic, Giuseppe Montalto, Giuseppa Castellino, Marcello Noto, Alessandro Parrino, and Manfredi Rizzo, “Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici,” Giornale Italiano di Cardiologia, vol. 17, no. 4, pp. 253–258, 2016. View at Publisher · View at Google Scholar
  • Karla Mayfield, Dan Siskind, Karl Winckel, Anthony W. Russell, Steve Kisely, Greg Smith, and Samantha Hollingworth, “Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes,” Journal Of Psychopharmacology, vol. 30, no. 3, pp. 227–236, 2016. View at Publisher · View at Google Scholar
  • Sheena Kayaniyil, Greta Lozano-Ortega, Heather A. Bennett, Kristina Johnsson, Alka Shaunik, Susan Grandy, and Bernt Kartman, “A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus,” Diabetes Therapy, vol. 7, no. 1, pp. 27–43, 2016. View at Publisher · View at Google Scholar
  • Na Wang, Jin-Ping Zhang, Xiao-Yan Xing, Zhao-Jun Yang, Bo Zhang, Xin Wang, and Wen-Ying Yang, “Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment,” Journal of Diabetes, 2016. View at Publisher · View at Google Scholar
  • A. J. Page, and S. J. Kentish, “Plasticity of gastrointestinal vagal afferent satiety signals,” Neurogastroenterology & Motility, 2016. View at Publisher · View at Google Scholar
  • Lalita Prasad-Reddy, Sneha Baxi Srivastava, and Diana Isaacs, “Role of glucagon-like peptide 1 receptor agonists in management of obesity,” American Journal of Health-System Pharmacy, vol. 73, no. 19, pp. 1493–1507, 2016. View at Publisher · View at Google Scholar
  • William B. White, and William L. Baker, “Cardiovascular effects of incretin-based therapies,” Annual Review of Medicine, vol. 67, pp. 245–260, 2016. View at Publisher · View at Google Scholar
  • Francesco Zaccardi, Zin Zin Htike, David R. Webb, Kamlesh Khunti, and Melanie J. Davies, “Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments A Systematic Review and Network Meta-analysis,” Annals Of Internal Medicine, vol. 164, no. 2, pp. 102–+, 2016. View at Publisher · View at Google Scholar
  • Mark M Smits, Daniel H van Raalte, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, and Djuna L Cahen, “GLP-1 based therapies: clinical implications for gastroenterologists,” Gut, vol. 65, no. 4, pp. 702–711, 2016. View at Publisher · View at Google Scholar
  • Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde, and Óscar Escribano, “Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications,” International Journal of Endocrinology, vol. 2016, pp. 1–15, 2016. View at Publisher · View at Google Scholar
  • Carol H. Wysham, Julio Rosenstock, Marion L. Vetter, Fang Dong, Peter Öhman, and Nayyar Iqbal, “Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, 2017. View at Publisher · View at Google Scholar
  • Robert S. Busch, and Michael P. Kane, “Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes,” Postgraduate Medicine, pp. 1–12, 2017. View at Publisher · View at Google Scholar
  • Qiuhe Ji, “Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-Like Peptide-1 Receptor Agonists,” Clinical Therapeutics, 2017. View at Publisher · View at Google Scholar
  • Zin Z. Htike, Francesco Zaccardi, Dimitris Papamargaritis, David R. Webb, Kamlesh Khunti, and Melanie J. Davies, “Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis,” Diabetes, Obesity and Metabolism, 2017. View at Publisher · View at Google Scholar
  • Marcel H.A. Muskiet, Mark M. Smits, Daniël H. Van Raalte, Lennart Tonneijck, Michaël J.B. Van Baar, Mark H.H. Kramer, Ewout J. Hoorn, and Jaap A. Joles, “GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes,” Nature Reviews Nephrology, vol. 13, no. 10, pp. 605–628, 2017. View at Publisher · View at Google Scholar
  • Yilmaz Atay, Murat Aslan, and Halife Kodaz, “A Swarm Intelligence-Based Hybrid Approach for Identifying Network Modules,” Journal of Computational Science, 2017. View at Publisher · View at Google Scholar
  • Jiali Liu, Ke Deng, Chang Xu, Jason W Busse, Per Olav Vandvik, Sheyu Li, Gordon H Guyatt, Xin Sun, and Ling Li, “Incretin based treatments and mortality in patients with type 2 diabetes: Systematic review and meta-analysis,” BMJ (Online), vol. 357, 2017. View at Publisher · View at Google Scholar
  • Michaël J.B. van Baar, Charlotte C. van Ruiten, Marcel H.A. Muskiet, Liselotte van Bloemendaal, Richard G. IJzerman, and Daniël H. van Raalte, “SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management,” Diabetes Care, vol. 41, no. 8, pp. 1543–1556, 2018. View at Publisher · View at Google Scholar
  • Maria J. Pereira, Per Lundkvist, Prasad G. Kamble, Joey Lau, Julian G. Martins, C. David Sjöström, Volker Schnecke, Anna Walentinsson, Eva Johnsson, and Jan W. Eriksson, “A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss,” Diabetes Therapy, 2018. View at Publisher · View at Google Scholar
  • Fang-Hong Shi, Hao Li, Min Cui, Zai-Li Zhang, Zhi-Chun Gu, and Xiao-Yan Liu, “Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” Frontiers in Pharmacology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • Tatiana I Romantsova, “Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity,” Obesity and metabolism, vol. 15, no. 1, pp. 3–11, 2018. View at Publisher · View at Google Scholar
  • Chiesa, Perna, Faliva, Naso, Pacifico, Lenzi, Rondanelli, Poggiogalle, and Donini, “Does endogenous GLP-1 affect resting energy expenditure and fuel selection in overweight and obese adults?,” Journal of Endocrinological Investigation, vol. 41, no. 4, pp. 439–445, 2018. View at Publisher · View at Google Scholar
  • Yingmei Zhang, James R. Sowers, and Jun Ren, “Targeting autophagy in obesity: from pathophysiology to management,” Nature Reviews Endocrinology, 2018. View at Publisher · View at Google Scholar
  • Xin-Kui Liu, Kai-Huan Wang, Bing Zhang, Xiao-Jiao Duan, Ying-Ying Cui, Dan Zhang, Di Tan, Shi Liu, Jia-Rui Wu, and Xiao-Meng Zhang, “Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: A network meta-analysis of randomized controlled trials,” BMC Complementary and Alternative Medicine, vol. 18, no. 1, 2018. View at Publisher · View at Google Scholar
  • Farheen K. Dojki, and George L. Bakris, “Blood Pressure Control and Cardiovascular/Renal Outcomes,” Endocrinology and Metabolism Clinics of North America, vol. 47, no. 1, pp. 175–184, 2018. View at Publisher · View at Google Scholar
  • Alessio Basolo, Joshua Burkholder, Kristy Osgood, Alexis Graham, Sarah Bundrick, Joseph Frankl, Paolo Piaggi, Marie S. Thearle, and Jonathan Krakoff, “Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: A Randomized, Double-blind, Placebo-Controlled Trial,” Metabolism, 2018. View at Publisher · View at Google Scholar
  • Qian Zhang, Xinhua Xiao, Jia Zheng, Ming Li, Miao Yu, Fan Ping, Tong Wang, and Xiaojing Wang, “Liraglutide protects cardiac function in diabetic rats through the PPARα pathway,” Bioscience Reports, vol. 38, no. 2, pp. BSR20180059, 2018. View at Publisher · View at Google Scholar
  • Marcel H A Muskiet, David C Wheeler, and Hiddo J L Heerspink, “New pharmacological strategies for protecting kidney function in type 2 diabetes,” The Lancet Diabetes & Endocrinology, 2018. View at Publisher · View at Google Scholar
  • J. Michael Gonzalez-Campoy, “Hormonal Regulation of Energy Balance and Energy Stores,” Bariatric Endocrinology, pp. 37–57, 2018. View at Publisher · View at Google Scholar
  • Chang Guo, Jin-Chao Zhang, Yi-Qiong Sun, and Qiang Li, “MiR-7, miR-9 and miR-375 contribute to effect of Exendin-4 on pancreatic β-cells in high-fat-diet-fed mice,” Clinical and Investigative Medicine, vol. 41, no. 1, pp. E16–E24, 2018. View at Publisher · View at Google Scholar
  • Zhong-Xia Lu, Wen-Jun Xu, Yang-Sheng Wu, Chang-Yu Li, and Yi-Tao Chen, “Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay,” Journal of Diabetes Research, vol. 2018, pp. 1–9, 2018. View at Publisher · View at Google Scholar
  • Hakan Dogruel, and Mustafa Kemal Balci, “Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future,” World Journal of Diabetes, vol. 10, no. 8, pp. 446–453, 2019. View at Publisher · View at Google Scholar
  • Irene Romera, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego, and Ana Cebrián-Cuenca, “A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes,” Diabetes Therapy, vol. 10, no. 1, pp. 5–19, 2019. View at Publisher · View at Google Scholar
  • Kaihuan Wang, Jiarui Wu, Xiaojiao Duan, Dan Zhang, Xi Lin, Sixuan Zhang, Mengwei Ni, Shuyu Liu, Ziqi Meng, Xiaoyan Gao, Peng Tan, and Yonggang Liu, “Comparative efficacy of Chinese herbal injections for angina pectoris: A Bayesian network meta-analysis of randomized controlled trials,” Complementary Therapies in Medicine, 2019. View at Publisher · View at Google Scholar